Experimental treatment strategies using human umbilical cord blood mononuclear cells (hUCB MNCs) represent a promising option for alternative stroke therapies. An important point for clinical translation of such treatment approaches is knowledge on the therapeutic time window. Although expected to be wider than for thrombolysis, the exact time window for hUCB MNC therapy is not known. Our study aimed to determine the time window of intravenous hUCB MNC administration after middle cerebral artery occlusion (MCAO). Male spontaneously hypertensive rats underwent MCAO and were randomly assigned to hUCB MNC administration at 4, 24, 72, and 120 or 14 days. Influence of cell treatment was observed by magnetic resonance imaging on days 1, 8, and 29 following MCAO and by assessment of functional neurological recovery. On day 30, brains were screened for glial scar development and presence of hUCB MNCs. Further, influence of hUCB MNCs on necrosis and apoptosis in postischemic neural tissue was investigated in hippocampal slices cultures. Transplantation within a 72-h time window resulted in an early improvement of functional recovery, paralleled by a reduction of brain atrophy and diminished glial scarring. Cell transplantation 120 h post-MCAO only induced minor functional recovery without changes in the brain atrophy rate and glial reactivity. Later transplantation (14 days) did not show any benefit. No evidence for intracerebrally localized hUCB MNCs was found in any treatment group. In vitro hUCB MNCs were able to significantly reduce postischemic neural necrosis and apoptosis. Our results for the first time indicate a time window of therapeutic hUCB MNC application of at least 72 h. The time window is limited, but wider than compared to conventional pharmacological approaches. The data furthermore confirms that differentiation and integration of administered cells is not a prerequisite for poststroke functional improvement and lesion size reduction.
INTRODUCTION
therapy to date, vessel recanalization by recombinant tissue plasminogen activator, is limited by a narrow time window of only 4.5 h (19). Within this time window Ischemic stroke is one of the most frequent causes of death and the most common reason for permanent therapeutic efficacy is reduced continuously, accompanied by an increasing probability of serious complica-disabilities in adults throughout industrialized nations (16). Despite vigorous research during the last decades, tions such as hemorrhages (20) . Consequently, there is a strong demand for alternative strategies, in particularly treatment opportunities are limited. The only approved for approaches expanding the time for intervention. wash, cell viability was assessed using 0.4% trypan blue in a Neubauer counting chamber to exclude dead cells Among these, transplantation of neonatal or adult stem cell-containing populations seems promising (28, 41) . and to ensure an adequate number of vital cells for transplantation or cocultivation. For in vivo transplantation, Therapeutic effects of intravenous administration of human umbilical cord blood mononuclear cells (hUCB volume was adjusted for a total amount of 1 × 10 6 hUCB MNCs per 1 ml and injected immediately. For direct cell MNCs), the most important source of neonatal stem cells, have already been demonstrated in rodents (7) . application on postischemic hippocampal slices, 2.5 × 10 4 hUCB MNCs were suspended in 1 µl Neurobasal-A Later studies confirmed beneficial impact of hUCB MNCs when transplanted between 8 and 48 h upon medium and applied on slices. stroke onset, as reviewed by Yu and colleagues (42).
Induction of Stroke and Cell Administration However, it is still unclear whether or not there is a time window for an effective hUCB MNC transplantation.
Forty-eight animals were subjected to permanent middle cerebral artery occlusion (MCAO) and randomly This hypothetical time window is of particular interest for clinical translation. It may be assumed that the thera-assigned to six experimental groups (n = 8 each): intravenous transplantation of 1 × 10 6 hUCB MNCs at 4, 24, peutic benefit of hUCB MNC administration following stroke is in fact transient, as integration and neuronal 72, and 120 h, or 14 days following stroke onset. Controls received 1 ml PBS after 24 h. Animals were anes-differentiation of grafted cord blood cells in the recipient central nervous system (CNS) seems to be a very rare thetized with ketamine hydrochloride (100 mg/kg, Merial, Germany), xylacine (10 mg/kg, Bayer, Ger-event (7) . Moreover, these processes are possibly not even related to functional improvement and reduction of many), and atropine (0.1 mg/kg, Ratiopharm, Germany) given as an intraperitoneal injection. Experimental ischemic lesion size (6) . Therapeutic effects of transplanted hUCB MNCs are more likely mediated by the stroke was induced by permanent distal (cortical) MCAO, as described previously (17) . During surgery, production of molecular mediators in a neuroprotective, antiapoptotic, or immunomodulatory manner (14) . These core body temperature was continuously monitored and maintained using a feedback controlled heating pad con-mechanisms in turn are bound to specific temporal and spatial kinetics of pathophysiological processes follow-nected to a rectal probe (Fine Science Tools, Germany). Heads of the animals were fixed in a flexible face mask ing stroke (10) . This emphasizes the importance of the appropriate transplantation time point. The current study over which O 2 -enriched air was applied. For analgesia postsurgery rats received 25 mg Metamizole-Na (Ratio-investigates the time-dependent efficacy of a hUCB MNC treatment following experimental brain ischemia. pharm) in 40 ml of 5% glucose drinking solution for at least 5 days following MCAO. One subject from the 72-MATERIALS AND METHODS h group died during the surgical procedure. Cell suspen-Experimental Subjects sion or vehicle solution was injected via intravenous catheter into a lateral tail vein within one minute. All All experiments were performed in accordance with experimental procedures were performed by investigathe European Communities Council Directive (86/609/ tors blinded to group allocation. EEC) and with local guidelines for care and use of For histological positive control of intracerebrally experimental animals. Animals were housed under conlocated PKH26-labeled cells, three additional rats were stant conditions of temperature (22°C), humidity (80%), used. These animals received intracerebral transplantaand light (12/12-h light/dark cycle). A total of 51 male tion of PKH26-labeled hUCB MNCs. Two depots conspontaneously hypertensive rats (SHR, Charles River, taining 5 µl of cell suspension (with 1.5 × 10 5 hUCB Germany), weighting 200-250 g were used in this study.
MNCs in each depot) were transplanted using a stereo- Behavioral Phenotyping stored, and thawed (in vitro study) as described elsewhere (32) . Prior to experiments, cells where prelabeled Sensorimotor functions were regularly assessed using the BeamWalk and modified Neurological Severity using the fluorescence dye PKH26 (Sigma, USA) according to the manufacturer's instructions, centrifuged Score (mNSS) tests following MCAO. In the BeamWalk test rats had to cross a narrow beam (14 mm diameter, at 1250 rpm for 5 min at 4°C, and washed three times with phosphate-buffered saline (PBS). After the final 1 m length) at the end of which the animal's home cage was placed (18). A score of 20 s was recorded if the PFA followed by storage in ascending concentrations of sucrose (10%, 20%, 30%) for 24 h each, and finally animals hugged the beam, and 30 s were recorded when they fell off the beam. After a training phase of 7 days stored at −80°C. The cryopreserved brains were cut in 30-µm-thick slices and mounted on Superfrost slides prior to surgery, baseline values were recorded as the mean of five trials. The mNSS was performed according (Resolab, Germany). Immunohistochemistry was performed for astrocytes, using mouse anti-glial fibrillary to Chen and colleagues (7) . Animals were investigated using both tests before experimental stroke for presurgi-acidic protein (GFAP, 1:100; Sigma) and for human cells using mouse anti-human nuclei (HuNu (MAB1281), cal deficits and after MCAO on days 1, 4, 7, 11, 15, 19, 23, and 27.
1:50; Millipore, Germany) as primary antibodies according to manufacturer instructions. The primary antibody To reveal possible differences between groups treated at 4, 24, and 72 h and controls, subjects were further was incubated with the slices in 0.9% PBS-Tween and 10% fetal cow serum (FCS) for 24 h at 4°C. Thereafter, investigated using the RotaRod (TSE Systems, Germany) on days 1, 2, 4, 7, 11, 17, 23, and 29 (7) following a 4-slices were washed and incubated with a secondary antibody conjugated with fluorescence isothiocyanate-con-day training phase and baseline assessment. The rod was continuously accelerated from 5 rpm and final rotation jugated anti-mouse (FITC, 1:200; Sigma-Aldrich, for GFAP) or cyanine 3 (Cy3, 1:200, Sigma-Aldrich, for speed (40 rpm) was reached after 180 s. A trial ended when the animals fell off the rung or after remaining on human nuclei), 0.9% PBS-Tween, and 10% FCS at room temperature for 1 h. After the final wash, the slides were the rod for more than 300 s. Mean was calculated from five individual trials per day. Animals were allowed to air-dried and cover-slipped. Nuclei were counterstained with DAPI (Sigma-Aldrich) for colocalization of recover in their home cages for at least 3 min before a new trial was started. Variables measured were quoted PKH26 signals with cells in the host brain. Slices were screened using an Axioplan fluorescence microscope as percentage of baseline values.
(Carl Zeiss, Germany) and, for detection of intracere-Magnetic Resonance Imaging (MRI) and Data Analysis brally located cells, using a Zeiss LSM710 confocal laser scanning microscope (Carl Zeiss). Spleen slices Five animals of each group treated at 120 h or less and controls were randomly selected to undergo MRI from animals that did not receive hUCB MNCs served as negative controls. investigations at 23 h and on days 8 and 29 following MCAO. Animals were anesthetized intraperitoneally as For appraisal of glial reactivity, the lesioned hemisphere was photographed up to 750 µm from the edge described above and placed in a 1.5 T MRI scanner (Gyroscan Intera human whole body spectrometer, Phil-of the infarct border using Axioplan fluorescence microscope (Carl Zeiss). GFAP-positive cells were quantified ips, The Netherlands) equipped with a small loop radiofrequency (RF) coil (47 mm; Microscopy Coil, Philips).
in this area using an automated counting software (Axiovision, Carl Zeiss), and quoted in to the exact size of the T2-weighted and T2*-weighted [T2*-fast field echo (FFE), to exclude intracerebral bleedings] sequences investigated area (events/mm 2 ). were performed at each MRI session, consisting of 20 hUCB MNC Cocultivation With Oxygen/ transverse slices (matrix: 224 × 224; field of view: 50
Glucose-Deprivated Hippocampal Slice Cultures mm; slice thickness: 1 mm). All sequences were measured as turbo-spin echo sequence. Data set evaluation Organotypic hippocampal slice cultures were prepared from postnatal Wistar rats (P7-P9; Harlan Winkel-was performed on coronal T2 weighted images using ImageJ (1) . Volumes of the lesion, of the ipsilateral and mann, Germany) as described previously (31). Briefly, hippocampi were dissected from brains and transversely the contralateral side ventricles, and of both hemispheres were assessed. Ischemic tissue loss was indicated by cut into 350 µm thick sections. Slices were maintained in 1 ml serum-based medium (50% MEM-Hanks, 25% brain atrophy being calculated as follows: the quotient between the size of the ipsilateral hemisphere minus the HBSS, 17 mM HEPES, 5 mM glucose, 1 mM L-glutamine, 25% horse serum, and 0.5% gentamycin) at 37°C infarct and the associated ventricle and the contralateral hemisphere subtracted by the contralateral ventricle was for 3 days and subsequently transferred to serum-free medium (50% MEM-Hanks, 25% HBSS, 17 mM determined. For MRI lesion volumetry, a group comparison approach for day 8 and 29 was performed.
HEPES, 5 mM glucose, 1 mM L-glutamine, 25% Neurobasal-A, 0.5% B27, and 0.5% gentamycin) and kept at Relocalization of Transplanted hUCB MNCs 37°C for further 7 days. Oxygen glucose deprivation and Appraisal of Glial Reactivity (OGD) was started by transferring the slices into 1 ml glucose-free Ringer solution containing 10 mM manni-On day 30, animals were deeply anesthetized and transcardially perfused with 200 ml PBS for 10 min, and tol. Oxygen deprivation was induced by incubating the slices under 95% N 2 /5% CO 2 for 50 min at 37°C in a thereafter with 300 ml 4% paraformaldehyde (PFA) for 15 min. Brains were carefully removed and fixed in 4% gas-tight chamber. Normoxic control cultures were maintained for the same time in glucose-containing RESULTS Ringer solution. Following OGD, slices were transferred Transplantation of hUCB MNCs Within 72 h Induces to normoxic culturing conditions and cocultured with Functional Recovery 2.5 × 10 4 hUCB MNCs in 1 µl Neurobasal-A medium, Statistical analysis of functional deficits before and 1 given directly onto the slices.
day after stroke onset displayed uniform experimental groups. All groups showed a considerable reduction of Analysis of PI Incorporation and Caspase-3 Expression sensorimotor abilities compared to baseline in all behavioral tests applied (p < 0.01), but time course and Propidium iodide (PI, 2 µg/ml; Sigma) was added to amount of regression were different between the groups. the culture medium 24 h prior to the experimental use.
Defect amelioration after MCAO appeared homoge-Only PI-negative slices were selected for OGD. In the nously within experimental groups treated after 4 (Fig. experimental course, PI was added to the culture 1A, B), 24 h (Fig. 1C, D) , and 72 h ( Fig. 1E, F) . Those medium at 22, 46, or 70 h after OGD and slices were subjects showed an early onset of sensorimotor function densitometrically analyzed 2 h after PI was added. The amelioration within 4-7 days after hUCB MNC adminevaluation of caspase-3 expression was performed in istration, leading to sustained recovery in all tests (p < formalin-fixed und cryosectioned slices (4% formalin 0.05) ( Fig. 1A-F ). Although showing lower mean valfor 45 min, 20 µm). Briefly, slices were incubated with ues compared to controls, cell administration at 120 h rabbit anti-active caspase-3 antibody (1:5000; PBS/10% ( Fig. 1G , H) and 14 days ( Fig. 1I , J) after MCAO did FCS, R&D Systems, Germany) for 48 h at 4°C. As secnot induce statistically significant functional benefits in ondary antibody biotinylated goat-anti-rabbit (1:500;
the BeamWalk. In the mNSS test, a slight recovery was PBS/10% FCS Dianova, Germany) was added for 1 h. detected at days 23 and 27 (p < 0.05) ( Fig. 1H ). How-Subsequent to the reaction with alkaline phosphataseever, both groups already differed significantly at day 1 avidin-biotin complex (1:400; Vectastain Elite ABC-kit, (p = 0.04) and 4 (p = 0.01) post-MCAO, but not thereaf-Vector Laboratories, USA), the complex was visualized ter until day 23, with the control group showing worse by 3′,3-diaminobenzidine tetrahydrochloride (DAB, outcome. Thus, the particular group results have to be Dako, Germany). Slices were air dried and counterinterpreted very cautiously. stained with standard Nissl method. Quantification of The RotaRod test was performed to assess possible caspase-3-positive cells was performed in photographes slight differences in recovery after cell administration of the dentate gyrus (DG) using Zeiss Axiovision within 72 h ( Fig. 2A-C ) in comparison to control treatmicroscopy image analyzing software (Carl Zeiss). ment and late cell administration (day 14) ( Fig. 2D ). In Statistical Analysis accordance to BeamWalk and mNSS testing, cell administration was effective within 72 h (p < 0.05), but not Statistical analyses were performed by an independent biostatistician using the SPSS statistical software thereafter. Animals that received hUCB MNCs 24 h after MCAO tended to stay on the RotaRod compared (Version 11.5.1). Data were tested for Gaussian distribution. Normally distributed data of two independent vari-to animals that received cells at all other injection time points (Fig. 2B ). However, this difference was not statis-ables were analyzed using Student's t-test (MRI data sets, experiments with organotypic slices). Ill behaved tically significant. data (all other data sets) were subjected to the Mann-Timely Administration of hUCB MNCs Reduced Brain Whitney test. ANOVA or ANOVA on ranks were used Atrophy Rate After Experimental Stroke in case of three or more variables. Post hoc analysis was performed using Tukey's test. Statistical significance Morphologically, all groups showed a homogenous diffusion disturbance, indicating the lesion at 23 h fol-was considered for values of p < 0.05 according to standard conventions and indicated by single symbols (*, #).
lowing MCAO in MRI (Fig. 3A) . At day 29, control animals and subjects that received hUCB MNCs at For values of p < 0.01 double symbols (**, ##) are shown. All data are presented as mean ± SD. 120 h and later following MCAO showed a more pronounced enlargement of side ventricles (Fig. 3B , Intravenously Injected hUCB MNCs Were Not Detected in Host Brains After 30 Days white arrows), indicating more extensive brain atrophy.
Lesion volumetry revealed no differences in lesion size between the groups at day 1 (data not shown).
Intracerebrally located PKH26-positive cells were observed 30 days after local cell administration in the Group comparison of lesion volumetry on later days showed a pronounced reduction of lesion sizes in groups positive-control group (Fig. 4A) . In contrast, PKH26positive signals were not observed in brain specimens that received hUCB MNCs within 72 h after stroke (p < 0.05) (Fig. 3C ), but not thereafter. Further, analysis of of animals from all experimental groups that received intravenous hUCB MNC transplantation (Fig. 4B ). MR data sets revealed a significantly smaller brain atrophy on day 29 within the experimental groups 4 h (9.4 ± Although very rare, red fluorescence signals were observed in single slices, no PKH26-like fluorescence 4.7%), 24 h (5.4 ± 4.1%), and 72 h (8.4 ± 3.0%) compared to the control group (16.9 ± 2.7%, p < 0.01) and signal was found in close spatial relation to DAPIstained nuclei. These signals were therefore considered subjects treated at 120 h after stroke onset (11.6 ± 6.0%, p < 0.05) (all Fig. 3D ). Although a clear mean difference as scattered autofluorescence. PKH26-positive signals after local hUCB MNC injection were not located within between the group receiving hUCB MNCs at 120 h after stroke onset and controls, a statistically significant dif-astrocytes ( Fig. 4C) . We alternatively used an antibody against human nuclei to locate hUCB MNCs in the ference does not exist between these groups (p > 0.05). We did neither observe any signs of tumor formation brain. However, this was not successful as unspecific staining was observed in negative controls (spleen slices nor secondary bleedings at any day in any group (data not shown).
of rats that did not receive human cells) ( Fig. 4D, E) , prohibiting a reliable detection of intracerebrally located MCAO compared to the 120 h (p < 0.01) ( Fig. 5B ) and control groups (p < 0.01) (Fig. 5B ). The number of hUCB MNCs. Summarizing, there was no valid evidence for graft-derived resident cells in host brains after GFAP-positive cells was not significantly altered in animals treated with hUCB MNCs at 120 h compared to intravenous application. the control group (Fig. 5A) . Interestingly, diminished Decreased Glial Reactivity After hUCB MNC astroglial reactivity was not observed in a small strip Administration Within 72 h directly bordering the central necrosis ( Fig. 5C-G) .
The investigation of glial reactivity 30 days upon
Cocultivation With hUCB MNCs Reduced Neural MCAO displayed statistically significant differences in Necrosis and Apoptosis in Hippocampal Slices the amount of GFAP-positive cells within a 750-µm broad area adjacent to the infarct (p < 0.01) (Fig. 5A) .
On each day of investigation OGD injured organotypic hippocampal slice cultures showed significantly The density of GFAP-positive cells was significantly reduced in subjects treated 4, 24, and 72 h following increased leveles of PI incorporation, indicating necrosis compared to the normoxic control slices (Fig. 6A) . when hUCB MNCs were administered within 72 h after MCAO. In animals treated after 120 h upon MCAO However, cocultivation with hUCB MNCs caused a significant reduction of PI incorporation at days 1, 2, and onset, delayed functional improvement was detected in the mNSS. Later administration completely failed to 3 (p < 0.05) (Fig. 6A ) with a level of necrosis being comparable to normoxic controls.
induce recovery. Previous studies gave clear indications for a wider time window of hUCB MNC application The investigation of caspase-3 activity showed a distinct increase of caspase-3-positive apoptotic cells compared to thrombolysis (7) , ranging up to 48 h (24). However, even longer time windows exist for effective within the DG following OGD at days 1, 2, and 3 (Fig.  6B) . Number of caspase-3-postive apoptotic cells was transplantation of other adult cell populations after experimental stroke. For bone marrow stromal cells, also significantly smaller in normoxic control slices during the entire observation period and in hUCB MNC-treated being a promising option for stroke therapy (33), a therapeutic time window of even 1 month was reported (29) , hippocampal slices at days 1 and 2, but not at day 3 (Fig. 6B ). Representative micrographs of PI incorpora-raising the question whether there is a comparable window for hUCB MNC treatment. The behavioral data tion ( Fig. 6C-C′′) ,caspase-3 staining (Fig. 6D-D′′) after OGD, normoxic cultivation, and OGD slices in obtained in this study for the first time clearly indicate a time frame of at least 72 h for beneficial hUCB MNC coculture with hUCB MNCs are given for day 2.
administration after experimental stroke. In addition,
DISCUSSION
comparison of RotaRod results of groups that received Time Dependency of Functional Recovery After hUCB treatment within 72 h after MCAO did not reveal any MNC Application superiority of a certain transplantation time point. However, transplantation after 24 h resulted in best mean Sensorimotor assessment using BeamWalk and mNSS showed a significant functional improvement performance in the RotaRod from day 17 and in the mNSS from day 7 onwards. Although not being statisti-stroke without cerebral homing of grafted cells (6, 38) . Some authors even presume that central nervous system cally significant, this tendency may indicate 24 h as the optimal time point for transplantation. The number of entry of administered cells is not needed to induce beneficial effects (6) . Thus, neurofunctional improvements subjects per group might be too small to reveal small effect differences at a statistically significant level. Nev-could also be explained by absence of administered cells at later stages and may be related to processes outside ertheless, the observed time window is considerably wider than the time frame of conventional pharmacolog-the brain (38). It might be assumed that reduction of lesion size in relation to late transplantation and con-ical approaches, particularly thrombolysis. trols, obviously not based on differentiation and integra-Sustained Functional Recovery Is Related to Lesion tion of grafted cells in a larger scale, could be due to Size Reduction But Not to Cell Engraftment prevention of acute or delayed cell death in the recipient brain. In accordance with results of neurofunctional tests, there was a clear decrease of brain atrophy measured by Potential Role of Antiapoptotic Processes for Lesion MRI at day 29 in all groups that received hUCB MNC Size Reduction treatment within 72 h after MCAO. Brain atrophy reduction was not observed after later cell administration and Necrotic cell death following stroke is an immediate event taking place in the ischemic core within the first sustained behavioral improvement was absent in these groups. Although neural differentiation of hUCB cells 4-12 hours (4,12), leaving only limited time for successful intervention. Cell death at later time points is was previously shown (43) , graft-derived cells were not reliably detected in brain specimens in this study. Sev-mostly determined by antiapoptotic mechanisms, particularly in the ischemic penumbra (5) . The in vitro investi-eral other groups also reported beneficial effects of hUCB MNC administration at singular time points after gation in this study showed that hUCB MNCs can strongly diminish apoptosis and necrosis in postischemic after injury (9) . Inhibitory elements within the glial scar as chrondrotoin sulphate proteoglycans are upregulated hippocampal slices. Similar effects of hUCB MNCs had been described in other model systems (13, 14) and the in reactive astrocytes and are presumed to constrict neural outgrowth, a key mechanism of functional regenera-antiapoptotic effect itself is likely mediated by the release of neurotrophic factors and recovery enhancing tion, both in vitro and in vivo (23,30). A limitation of astrocytic reactivity therefore might ameliorate the effects from the grafted cells (11). Apoptotic processes following focal cerebral ischemia in rats occur within endogenous regeneration potentials, thus leading to beneficial effects of hUCB MNCs as observed in this study. 72 h after vessel occlusion (35, 39) . Thus, prevention of delayed cell death may result in reduced lesion volumes Assuming that the vast majority of glial scar tissue was formed in the host brain 120 h upon MCAO would and brain atrophy at later time. However, MRI-based lesion size comparison did not detect any differences in explain the minimal cell effect on functional outcome and absent impact on lesion size and astroglial reactivity lesion size between the groups at day 8. Albeit relevant antiapoptotic capabilities of hUCB MNCs in comparison at this time. to hUCB stem cell fractions were found in vitro (14, 25) , Current Controversies About the Beneficial Effect assessment of impact of hUCB MNC administration 24 of hUCB MNCs After Experimental Stroke h after MCAO on lesion size and caspase-3-dependent Some well designed studies were not able to reproapoptosis during the first 96 h following MCAO did not duce the beneficial effects of hUCB MNCs, especially reveal a statistically significant effect (26). Thus, antiapwhen using more demanding behavioral tests (22) . Howoptosis in penumbral tissue may contribute to lesion size ever, there are possibly relevant differences to our study. reduction to a minor extent but is unlikely the sole rea-First is the use of comorbid animals in our trial, which, son for decreased brain atrophy at day 29, which may even after cortical MCAO, show stronger defects and also be attributed to other processes diminishing cerebral larger infarct volumes compared to control strains (34) . tissue loss after stroke at later stages. It may further be This possibly allows better detection of a therapeutic concluded that novel in vitro systems providing a higher impact. Second, fresh cells were administered in our in predictive power for the in vivo situation are demanded.
vivo study while the use of cells being stored for 1 year or longer was reported by Mäkinen and colleagues (22) .
Further Beneficial Effects of hUCB MNC Application
Although hematopoietic potential and cell recovery rate After Stroke of hUCB cells are not affected even after 10 years of In fact, a clear regenerative potential beyond preventcryopreservation (40), equivalent information regarding ing necrosis in acute and after ischemic conditions was the neuroprotective or regenerative capacity following reported for hUCB MNCs. Cells were able to increase stroke is missing so far. Strain differences, freezing oligodendrocyte survival (27) , diminish peripheral time, and so far unconsidered differences in the freezinflammatory (21), or microglial (15) response and stiming/thawing protocols potentially may have contributed ulated neurogenesis (3). Moreover, hUCB and in particto differing results. This clearly emphasizes the imporular MNC subfractions promote angiogenesis (37) and tance to thoroughly address even "minor" or "technical" may prevent oxidative damage (2) . These processes can points during a later translational process into the clinic. lead to an overall reduction of lesion size and behavioral Optimal Time Window for hUCB MNC Transplantation improvements also at alter stages of cerebral ischemia, Following Stroke but might need relatively early induction following stroke.
Summarizing, beneficial effects of hUCB adminis-Possible Explanation of the Time Window tered within 72 h after MCAO were clearly shown by by Diminishing Gliosis three independent methods. The failure to induce sustained functional recovery, lesion size reduction, and Transplantation of hUCB MNCs influenced the formation of reactive gliosis. Quantification of GFAP-posi-limitation of glial scaring in animals treated 120 h following MCAO and thereafter indicates a time window tive reactive astrocytes in the present study showed a limitation of the glial scar extent when hUCB MNCs of at least 72 h for efficient cell application. Any therapeutic impact between these time points cannot be were administered within 72 h. Interestingly, astrocytic reactivity is known to develop within a time span of up excluded, but could be considered minor and/or declining based on the data obtained in our experiments. to 5 days while the time course of glial response was found peaking 72 h after stroke onset (8, 36) . It is well Although limited, the time span for hUCB MNC administration after experimental stroke is far beyond that of known that glial cells respond to ischemic damage and form the glial scar, but it is still uncertain whether this thrombolysis. Thus, hUCB MNCs are expected to be a promising tool for acute stroke treatment, which, how-response promotes or limits endogenous repair processes in the central nervous system. The glial scar constitutes ever, might require comparatively early intervention in the subacute phase of stroke. a chemical and physical barrier against sprouting axons
